S&P 500 7,323.63 −0.23%
Nasdaq 24,429.89 +0.42%
S&P/TSX 34,578.05 −2.09%
Apple 352.45 +0.15%
Nvidia 150.96 −2.89%
Microsoft 508.29 +0.40%
Shopify 199.78 −1.50%
Royal Bank 272.26 −3.11%
CAD/USD 0.6992 −0.02%
PRE-MKT · 05:55 ET
Market ClerkRecap
Thu Nov 19 · pre-market7 signals on Nov 18520 insider buys this week · $248.1MCIRO short report next: Nov 30The week ahead

YARW

Yarrow Bioscience, Inc.
NASDAQ · HEALTH CARE · PHARMACEUTICAL PREPARATIONS
14.35
+0.14 +0.99%
USD · close Nov 18

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

MKT CAP $38.3MP/E —DIV YIELD —FCF YIELD -86.46%REV TTM $570K +13.8%NET INCOME −$26.5MNET CASH $22.9M52W 13.60 – 46.15SEC XBRL · TTM TO Invalid Date

Financials

SEC XBRL · 51 PERIODS · WHOLE USD

By quarter

PeriodRevenueYoYGross marginOperating incomeNet incomeYoYEPSOp. cash flowCapexFree cash flowFiled
Q2 2026 · Jun 30$97K+15.5%—−$3.1M−$3M—-3.51−$2M——Aug 13
Q1 2026 · Mar 31$86K−28.9%—−$3.8M−$3.6M—-0.08−$4.1M——May 15
Q2 2025 · Jun 30$69K−65.2%—−$7.5M−$5.8M—-6.73−$10.8M——Aug 13
Q1 2025 · Mar 31$202K+106.1%—−$9.2M−$8.6M—-0.20−$11.5M——May 15
Q4 2024 · Dec 31derived$84K+10.5%—−$12.8M−$12M—-0.28−$9M——Feb 27
Q3 2024 · Sep 30$121K+6.1%—−$13.1M−$12.2M—-0.29−$8.5M——Nov 7
Q2 2024 · Jun 30$198K+46.7%—−$10.4M−$9.4M—-0.22−$8.5M——Aug 14
Q1 2024 · Mar 31$98K−1.0%—−$7.4M−$6.2M—-0.15−$8M——May 8
Q4 2023 · Dec 31derived$76K——−$6.8M−$6.2M—4.04−$5.1M——Mar 6
Q3 2023 · Sep 30$114K——−$6.2M−$6.6M—-2.01−$5.2M——Nov 7
Q2 2023 · Jun 30$135K——−$10.3M−$10.1M—-3.09−$9.6M——Aug 14
Q1 2023 · Mar 31$99K——−$5.9M−$5.6M—-1.74−$5.5M——May 9

By fiscal year

YearRevenueGross marginOperating incomeNet incomeNet marginEPSOp. cash flowCapexFree cash flowBuybacksDividends paid
FY2025 · to Dec 31$570K—−$29.7M−$26.5M-4646.1%-0.62−$33.1M$0−$33.1M——
FY2024 · to Dec 31$501K—−$43.6M−$39.8M-7950.9%-0.93−$34M$117K−$34.1M——
FY2023 · to Dec 31$424K—−$29.3M−$28.5M-6710.4%-2.78−$25.3M$0−$25.3M——
FY2022 · to Dec 31$477K—−$34.3M−$23.2M-4865.8%-7.28−$29.2M————
FY2021 · to Dec 31$931K-259.6%−$38.9M−$73.3M-7876.4%-25.64−$56.4M$0−$56.4M——
FY2020 · to Dec 31$21M93.4%−$252.5M−$255.6M-1217.4%7.88−$137.1M$113K−$137.2M——

Every number comes from Yarrow Bioscience, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.

Watch YARW. Know when insiders buy.
One email the day a filing lands. Free.